Detalles de la búsqueda
1.
Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease.
Biol Blood Marrow Transplant
; 26(2): 323-332, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31618690
2.
Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 25(8): 1526-1535, 2019 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30831208
3.
Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 25(6): 1136-1141, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30625387
4.
Impact of High-Molecular-Risk Mutations on Transplantation Outcomes in Patients with Myelofibrosis.
Biol Blood Marrow Transplant
; 25(6): 1142-1151, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30625392
5.
Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.
Br J Haematol
; 184(6): 1006-1010, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30537212
6.
Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 24(12): 2517-2522, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30055353
7.
Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 24(1): 142-149, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28951193
8.
Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 24(1): 133-141, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28870777
9.
Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34+ Selected and Unmodified Hematopoietic Stem Cell Transplantation.
Biol Blood Marrow Transplant
; 24(5): 1079-1087, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29325829
10.
CD34+ Cell Selection versus Reduced-Intensity Conditioning and Unmodified Grafts for Allogeneic Hematopoietic Cell Transplantation in Patients Age >50 Years with Acute Myelogenous Leukemia and Myelodysplastic Syndrome .
Biol Blood Marrow Transplant
; 24(5): 964-972, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29305194
11.
Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Older Patients with Myelodysplastic Syndromes.
Biol Blood Marrow Transplant
; 23(7): 1078-1086, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28336325
12.
T Cell Depletion as an Alternative Approach for Patients 55 Years or Older Undergoing Allogeneic Stem Cell Transplantation as Curative Therapy for Hematologic Malignancies.
Biol Blood Marrow Transplant
; 23(10): 1685-1694, 2017 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-28734876
13.
A Chemotherapy-Only Regimen of Busulfan, Melphalan, and Fludarabine, and Rabbit Antithymocyte Globulin Followed by Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplantations for the Treatment of Myeloid Malignancies.
Biol Blood Marrow Transplant
; 23(12): 2088-2095, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28711727
14.
Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34+ Selected Grafts for Allogeneic Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 23(1): 67-74, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27789361
15.
The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies.
Biol Blood Marrow Transplant
; 23(11): 2004-2011, 2017 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-28733264
16.
Ex Vivo CD34+-Selected T Cell-Depleted Peripheral Blood Stem Cell Grafts for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Leukemia and Myelodysplastic Syndrome Is Associated with Low Incidence of Acute and Chronic Graft-versus-Host Disease and High Treatment Response.
Biol Blood Marrow Transplant
; 23(3): 452-458, 2017 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28017734
17.
Cytomegalovirus Infection after CD34(+)-Selected Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 22(8): 1480-1486, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27178374
18.
Second Allogeneic Stem Cell Transplantation for Acute Leukemia Using a Chemotherapy-Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa.
Biol Blood Marrow Transplant
; 22(8): 1449-1454, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27184623
19.
The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months.
Br J Haematol
; 173(2): 260-4, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-26847389
20.
Allogeneic haematopoietic stem cell transplantation for primary myelofibrosis and myelofibrosis evolved from other myeloproliferative neoplasms.
Curr Opin Hematol
; 22(2): 184-90, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25635756